CA3143257A1 - Viral vector therapy - Google Patents

Viral vector therapy Download PDF

Info

Publication number
CA3143257A1
CA3143257A1 CA3143257A CA3143257A CA3143257A1 CA 3143257 A1 CA3143257 A1 CA 3143257A1 CA 3143257 A CA3143257 A CA 3143257A CA 3143257 A CA3143257 A CA 3143257A CA 3143257 A1 CA3143257 A1 CA 3143257A1
Authority
CA
Canada
Prior art keywords
gene therapy
moiety
compstatin analog
compstatin
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3143257A
Other languages
English (en)
French (fr)
Inventor
Cedric Francois
Lukas Scheibler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apellis Pharmaceuticals Inc
Original Assignee
Apellis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apellis Pharmaceuticals Inc filed Critical Apellis Pharmaceuticals Inc
Publication of CA3143257A1 publication Critical patent/CA3143257A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3143257A 2019-07-05 2020-07-02 Viral vector therapy Pending CA3143257A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962871058P 2019-07-05 2019-07-05
US62/871,058 2019-07-05
US201962871700P 2019-07-08 2019-07-08
US62/871,700 2019-07-08
US201962875925P 2019-07-18 2019-07-18
US62/875,925 2019-07-18
US201962935569P 2019-11-14 2019-11-14
US62/935,569 2019-11-14
PCT/US2020/040741 WO2021007111A1 (en) 2019-07-05 2020-07-02 Viral vector therapy

Publications (1)

Publication Number Publication Date
CA3143257A1 true CA3143257A1 (en) 2021-01-14

Family

ID=74114222

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3143257A Pending CA3143257A1 (en) 2019-07-05 2020-07-02 Viral vector therapy

Country Status (6)

Country Link
US (1) US20220249706A1 (cg-RX-API-DMAC7.html)
EP (1) EP3996744A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022539238A (cg-RX-API-DMAC7.html)
AU (1) AU2020311330A1 (cg-RX-API-DMAC7.html)
CA (1) CA3143257A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021007111A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180090785A (ko) 2015-10-07 2018-08-13 아펠리스 파마슈티컬스 인코포레이티드 투여 요법
BR112019020955A2 (pt) * 2017-04-07 2020-05-05 Apellis Pharmaceuticals, Inc. regimes de dosagem e composições e métodos relacionados
JP2021507884A (ja) 2017-12-15 2021-02-25 アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals,Inc. 投与レジメンならびに関連組成物および方法
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
MA71435A (fr) * 2021-05-27 2025-04-30 Apellis Pharmaceuticals, Inc. Édition génomique du complément
US20260043046A1 (en) * 2022-03-17 2026-02-12 Adverum Biotechnologies, Inc. Cassettes of anti-complement component 3 antibody, vectorization and theraputic application
EP4622992A1 (en) * 2022-11-24 2025-10-01 Amyndas Pharmaceuticals US LLC Compstatin analogs for vector-based therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000029033A2 (en) * 1998-11-17 2000-05-25 The General Hospital Corporation A method of genetic vector delivery
JP2007112715A (ja) * 2004-01-22 2007-05-10 Dnavec Research Inc 繰返し投与を伴うベクターの発現を継続させる方法
US10035822B2 (en) * 2012-11-15 2018-07-31 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
WO2015103438A2 (en) * 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity

Also Published As

Publication number Publication date
JP2022539238A (ja) 2022-09-07
AU2020311330A1 (en) 2022-02-17
EP3996744A4 (en) 2023-07-12
EP3996744A1 (en) 2022-05-18
US20220249706A1 (en) 2022-08-11
WO2021007111A1 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
US20220249706A1 (en) Viral vector therapy
US20230009757A1 (en) Combination therapy for c3 inhibition
US20250002910A1 (en) Treatment of complement-mediated disorders
US20230095695A1 (en) Rnas for complement inhibition
JP2019508020A (ja) 低反復性ヌクレオチド配列を有する、プロリンおよびアラニン残基が豊富な反復性アミノ酸配列をコードする核酸
KR20170116055A (ko) 최적화된 인간 응고 인자 viii 유전자 발현 카세트 및 그의 용도
JP2021502105A (ja) タンパク質操作された細胞外小胞
KR102549520B1 (ko) 비염증성 식세포작용 유도 활성을 갖는 융합분자
KR20220107243A (ko) Apoe 유전자 요법
US20220280598A1 (en) Complement inhibitor dosing regimens
SG187171A1 (en) Nucleophilic catalysts for oxime linkage
US20250075209A1 (en) Rnas for complement inhibition
US20250213730A1 (en) Gene therapy for diseases with cns manifestations
US12251395B2 (en) RNAS for complement inhibition
TWI922495B (zh) 用以於一患者中螯合非預期的抗peg抗體的化合物
US11840703B2 (en) Recombinant versican isoforms and related compositions and methods
EP4717771A1 (en) Reducing expression of proteinase 3 autoantigen in anca-associated vasculitis
US9670259B2 (en) Method of inhibiting angiogenesis using inhibitors of G-protein-coupled receptor kinase interacting protein-1 (GIT1)
TW202309279A (zh) 用於補體抑制之rna

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240523

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250627

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250627

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251127

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260319

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260323

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260323

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260323

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260626

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260626